“Improving Outcomes For Patients With Sepsis” — Interview from Progress, Potential & Possibilities

Roland Carlson interview for Progress Potential Possibilities

“Today we have the honor of being joined by Dr Roland Carlson, who is the Chief Executive Officer of Immuneexpress which is a Seattle-based molecular diagnostic company they’re committed to improving the outcomes for patients suspected of having sepsis and their FDA-cleared SeptiCyte technology is focused on rapidly quantifying from whole blood specific molecular markers…

Read More

Data Presentation at Association for Molecular Pathology 2023 Validates Performance of SeptiCyte® RAPID in Immunocompromised Patients and Patients on Immunosuppressive Therapy

Immunexpress - the signature diagnostics for sepsis

SeptiCyte® RAPID may aid clinicians in determining early antibiotic administration and in bundle compliance for immunocompromised patients with intermediate-high and high probabilities of sepsis SEATTLE and BRISBANE, Australia, Nov. 17, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected sepsis patients, today announced a poster presentation validating the utility of SeptiCyte® RAPID…

Read More